• Cullgen Appoints Dr. Mark Deeg to Lead Clinical Development

    10 days ago - By San Diego Biotechnology

    SAN DIEGO--Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that Mark Deeg, M.D., Ph.D., has joined the company as Executive Vice President of Clinical Development. Dr. Deeg is a well-respected leader with extensive experience...
    Read more ...